The Tool Desk
Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Pfizer has a notable income record: the company declared a third-quarter 2026 dividend of $0.43 per share and called it the 351st consecutive quarterly dividend. It also raised the midpoint of its 2026 revenue outlook. Those facts make Pfizer worth examining as a dividend stock, but they do not prove that the shares are undervalued or that the dividend is guaranteed. The case depends on whether the company can sustain earnings and cash generation as COVID-product revenue falls and exclusivity expirations pressure sales.
What makes Pfizer’s dividend appealing?
Pfizer declared a $0.43-per-share dividend for the third quarter of 2026, payable September 1, 2026. The company described it as its 351st consecutive quarterly dividend. Pfizer says its capital-allocation policy is to maintain and, over the longer term, grow the dividend; that is management’s stated policy, not a promise about future board decisions or payment capacity. Pfizer’s June 24, 2026 dividend announcement
Pfizer’s dividend history shows a quarterly amount of $0.43 in each quarter of 2025 and in the first three listed quarters of 2026, compared with $0.42 in each listed quarter of 2024. The payment history helps establish consistency and recent per-share growth, but neither alone establishes that the dividend is covered by current cash flow. Pfizer’s dividend history
What do the latest results say about the business?
In results released August 4, 2026, Pfizer reported second-quarter revenue of $15.0 billion, 3% higher than a year earlier; operational growth was 1%. Pfizer raised its full-year 2026 revenue guidance to $60.5 billion–$62.5 billion and reaffirmed adjusted diluted EPS guidance of $2.80–$3.00. These are company-reported results and guidance, not a forecast of what shareholders will earn. Pfizer’s second-quarter 2026 results exhibit filed with the SEC
#1 Best Overall
The guidance assumes about $4 billion in COVID-product revenue, down from Pfizer’s previous assumption of approximately $5 billion. Stronger expected performance from non-COVID products partly offsets that reduction. The outlook therefore depends in part on whether the rest of the business can compensate for continued weakness in COVID-related sales.
How serious is the patent-expiration risk?
Pfizer’s second-quarter 2026 Form 10-Q estimated that patent-based or regulatory exclusivity expirations would have an unfavorable revenue impact of approximately $1.1 billion in 2026. The company also described a broader sequence of expirations affecting products through 2030. The $1.1 billion figure is Pfizer’s forward-looking estimate, not a realized loss or an independent forecast. Pfizer’s second-quarter 2026 Form 10-Q
Rank #2
For dividend investors, the key issue is not simply that exclusivity expires, but whether new products and other revenue can replace sales quickly enough to support earnings and cash generation. The figures available here do not provide a full cash-flow payout-coverage analysis, so they are not enough to conclude that the dividend is safe or at risk.
Can Pfizer’s pipeline replace lost revenue?
Pfizer reported 95 total pipeline programs as of August 4, 2026, including 31 in Phase 3 and two in registration. These counts show the scale and stage of the development portfolio, not the amount or timing of future sales. Candidates can fail, face delays, or reach the market without achieving commercial success; approvals, market access, and uptake all remain uncertain. Pfizer’s investor-relations overview and pipeline snapshot
Free tools Windows power users keep installed
One-click scans. No signup required.
That makes the pipeline relevant to the replacement question, but not a substitute for evidence about likely revenue. Investors weighing the dividend should look for commercial progress and cash generation as well as development milestones.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Is Pfizer undervalued right now?
The available company information establishes a dividend amount, operating results, management guidance, risks, and a dated pipeline count. It does not establish a current share price, dividend yield, valuation multiple, analyst consensus, or independent fair-value estimate. Without a dated price and an explicit comparison—such as forward earnings or free-cash-flow yield—calling Pfizer undervalued would go beyond the evidence.
Rank #4
Before making a decision, compare the share price you can actually trade with the company’s updated earnings and cash-flow outlook. For an income-focused analysis, calculate yield using that dated price and assess the dividend against cash flow and debt; the payment record by itself cannot answer either question.
Quick Recap
How to weigh the dividend-stock case
- Income evidence: A $0.43 quarterly dividend was declared for Q3 2026, and Pfizer reported a long record of consecutive quarterly dividends.
- Near-term business evidence: Q2 2026 revenue rose year over year, and the company raised its 2026 revenue-guidance midpoint, while reducing its COVID-product revenue assumption.
- Longer-term uncertainty: Pfizer estimates exclusivity expirations will weigh on 2026 revenue and lists a substantial pipeline, but pipeline counts do not demonstrate successful replacement revenue.
- Valuation gap: No current price or valuation measure is established here, so the “underrated” claim cannot be confirmed from these facts alone.
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
Do these 3 things before closing this tab:
1Clear out junk files and repair common Windows errors2Fix the driver behind crashes, sound loss and screen glitches3Repair Windows errors before they cause bigger problems
